Diagnosis and treatment strategies for solid organ transplant recipients with SARS-CoV-2 infection
10.3969/j.issn.1674-7445.2023.02.002
- VernacularTitle:实体器官移植受者感染新型冠状病毒的诊疗策略
- Author:
Chunrong JU
1
;
Xin XU
;
Wujun XUE
Author Information
1. Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510012, China
- Publication Type:Research Article
- Keywords:
SARS-CoV-2;
Solid organ transplant recipient;
Epidemiology;
Nucleic acid test;
Nematvir/ritonavir;
Remdesivir;
Renal replacement therapy;
Transplant-associated thrombotic microangiopathy;
Multi-disciplinary team (MDT)
- From:
Organ Transplantation
2023;14(2):183-
- CountryChina
- Language:Chinese
-
Abstract:
Due to long-term use of immunosuppressive agents, solid organ transplant recipients (SOTR) belong to high-risk populations of multiple pathogenic infection, including SARS-CoV-2. In addition, SOTR are constantly complicated by chronic diseases, such as hypertension and diabetes mellitus, etc. After infected with SARS-CoV-2, the critically ill rate and fatality of SOTR are higher than those of the general population, which captivates widespread attention from experts in the field of organ transplantation. Omicrone variant is currently the significant pandemic strain worldwide, rapidly spreading to more than 100 countries worldwide and causing broad concern. According to the latest international guidelines on the diagnosis and treatment of SARS-CoV-2 infection and relevant expert consensus in China combined with current domestic situation of SARS-CoV-2 pandemic and China's "diagnosis and treatment regimen for SARS-CoV-2 infection (Trial Version 10)", the epidemiology, clinical manifestations and prognosis, diagnosis, clinical classification and treatment of SARS-CoV-2 infection were briefly reviewed.
